First Wave Rises With Sanofi GI Deal
Executive Summary
First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.
Topics
- Subjects
- Deals
- Artificial Intelligence
- Commercial
- Business Strategies
- Therapy Areas
- Gastrointestinal
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC149052
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC149052
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.